암 면역치료 시장 규모는 향후 몇 년동안 연평균 11.6%의 성장률을 보이며 2029년에는 1,946억 4,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 암 치료에 대한 새로운 면역치료 승인 증가, 개인 맞춤형 의료에 대한 수요 증가, 암 진단 사례 증가, 첨단 치료법 도입을 위한 임상시험에 대한 투자 증가, 암 면역치료에 대한 인식 증가 등에 기인합니다. 예측 기간의 주요 동향으로는 CAR T 세포를 포함한 입양 세포 치료의 등장, 암 면역 치료에서 종양 용해성 바이러스의 탐색, 개인 맞춤형 암 백신 개발, 면역 치료 연구에서 인공지능의 활용, 치료 결정에 있어 실제 증거와 환자 결과의 중요성 증가 등을 꼽을 수 있습니다.
암 발병률 증가는 암 면역치료제 시장을 촉진할 것으로 예상됩니다. 전 세계적으로 암 발병률이 증가하는 요인으로는 담배, 알코올, 비만, 좌식 생활습관, 환경적 요인 등이 있습니다. 이러한 암 환자 증가는 암 면역치료에 대한 수요를 증가시킬 것으로 예상됩니다. 환자들은 보다 회복력이 높고 통증을 최소화하는 치료에 투자하고 있기 때문입니다. 예를 들어, 벨기에에 본부를 둔 유럽연합 집행위원회의 공동 연구센터인 유럽연합 과학 허브에 따르면, 2023년 10월 신규 암 환자는 지난 2년 동안 2.3% 증가하여 2022년에는 274만 명에 달할 것으로 예상했습니다. 마찬가지로, 암으로 인한 사망자 수는 지난 2년간 2.4% 증가했습니다. 따라서 암 발병률 증가는 예측 기간 동안 암 면역치료에 대한 수요를 증가시킬 것으로 예상됩니다.
바이오시밀러 증가로 암 면역치료제 시장의 성장은 향후 몇 년동안 가속화될 것으로 예상됩니다. 바이오시밀러는 기존 승인된 생물학적 제제(오리지널 의약품)와 매우 유사한 생물학적 의료제품으로, 오리지널 의약품과 안전성, 유효성, 품질에 있어 임상적으로 중요한 차이가 없도록 설계되어 있습니다. 바이오시밀러 의약품은 치료 접근성을 높이고, 경쟁을 촉진하고, 가격을 낮추며, 암 환자들에게 보다 지속 가능하고 다양한 치료 옵션을 제공하기 때문에 암 면역치료에서 큰 잠재력을 가지고 있습니다. 예를 들어, 미국 바이오제약사 Amgen Inc.에 따르면, 2022년 2분기 기준 FDA의 바이오시밀러 개발 프로그램에 등록된 바이오시밀러 의약품은 96개 품목으로 70% 가까이 증가했다고 합니다. 따라서 바이오시밀러 증가가 암 면역치료제 시장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나재난, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 암 면역치료 시장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 이용 산업 분석
- 세계의 암 면역치료 시장 성장률 분석
- 세계의 암 면역치료 시장 실적 : 규모와 성장, 2019-2024년
- 세계의 암 면역치료 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계의 암 면역치료 유효 시장(TAM)
제6장 시장 세분화
- 세계의 암 면역치료 시장 : 제품별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 단클론항체
- 체크포인트 억제제
- 면역 조절제
- 백신
- 세포치료
- 세계의 암 면역치료 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 폐암
- 유방암
- 대장암
- 흑색종
- 전립선암
- 다발성 골수종
- 세계의 암 면역치료 시장 : 최종사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 병원
- 암 연구센터
- 클리닉
- 세계의 암 면역치료 시장 : 단클론항체 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 키메라 단클론항체
- 인간화 단클론항체
- 완전 인간형 단클론항체
- 세계의 암 면역치료 시장 : 체크포인트 억제제 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- PD-1 억제제
- PD-L1억제제
- CTLA-4 억제제
- 세계의 암 면역치료 시장 : 면역 조절제 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 사이토카인
- 종양용해성 바이러스
- Toll-Like Receptor (TLR) Agonists
- 세계의 암 면역치료 시장 : 백신 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 암 예방 백신
- 치료용 암 백신
- 세계의 암 면역치료 시장 : 세포치료 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- CAR T세포 치료
- TCR 요법
- NK 세포(NK)치료
제7장 지역별/국가별 분석
- 세계의 암 면역치료 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 암 면역치료 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 암 면역치료 시장 : 경쟁 구도
- 암 면역치료 시장 : 기업 개요
- Amgen Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd
- Bayer AG
- Eli Lilly and Company
제31장 기타 주요 기업 및 혁신 기업
- 3D Signatures Inc.
- Adaptive Biotechnologies Corp.
- Argos Therapeutics Inc.
- Bristol-Myers Squibb Company
- Cell Medica Limited
- Cellular Biomedicine Group Inc.
- Gilead Sciences Inc.
- Gradalis Inc.
- Immatics Biotechnologies GmbH
- Iovance Biotherapeutics Inc.
- Juno Therapeutics LLC
- Kura Oncology Inc.
- MacroGenics Inc.
- Merck & Co. Inc.
- Neon Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 시장의 최근 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 암 면역치료 시장(2029년) - 가장 새로운 기회를 제공하는 국가
- 암 면역치료 시장(2029년) - 가장 새로운 기회를 제공하는 부문
- 암 면역치료 시장(2029년) - 성장 전략
제36장 부록
LSH
Cancer immunotherapy refers to a type of cancer therapy that strengthens your body's defenses against the disease. Your body's immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.
The main types of products of cancer immunotherapy are monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy. Monoclonal antibodies are man-made proteins that function in the immune system such as human antibodies. Cancer immunotherapy is used to treat lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and multiple myeloma. These are used in hospitals, cancer research centers, and clinics.
The cancer immunotheraphy market research report is one of a series of new reports from The Business Research Company that provides cancer immunotheraphy market statistics, including cancer immunotheraphy industry global market size, regional shares, competitors with a cancer immunotheraphy market share, detailed cancer immunotheraphy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotheraphy industry. This cancer immunotheraphy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cancer immunotherapy market size has grown rapidly in recent years. It will grow from $110.91 billion in 2024 to $125.68 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising prevalence of cancer, increased adoption of immunotherapy over traditionalTherapy, growing r&d activities forThe development of targeted diseases, increased effectivity and accuracy of newerTherapies, growing recognition of The limitations of traditional cancer treatments.
The cancer immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $194.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing approval of novel immunotherapies for cancer treatment, growing demand for personalized medicine, rising cases of people being detected with cancer, increasing investment in clinical trials to introduce cutting-edge treatments, growing awareness about cancer immunotherapy. Major trends in the forecast period include emergence of adoptive cell therapies, including car-t cells, exploration of oncolytic viruses in cancer immunotherapy, development of personalized cancer vaccines, utilization of artificial intelligence in immunotherapy research, increasing emphasis on real-world evidence and patient outcomes in treatment decisions.
The rise in cancer incidence is expected to propel the cancer immunotherapy market. The factors contributing to the growth in cancer cases across the globe include tobacco, alcohol, obesity, a sedentary lifestyle, and environmental factors. This growth in cancer cases is expected to boost demand for cancer immunotherapies, as patients are increasingly investing in medical treatments with greater recovery and minimal pain. For instance, in October 2023, according to the European Union Science Hub, a Belgium-based European Commission's Joint Research Centre, new cancer cases increased by 2. 3% during the preceding two years, reaching 2. 74 million in 2022. Similarly, cancer fatalities increased by 2. 4% during the preceding two years. Therefore, the increase in cancer incidence is expected to boost demand for cancer immunotherapy during forecast period.
The increasing emergence of biosimilars is expected to propel the growth of the cancer immunotherapy market in the coming years. Biosimilars are biological medical products that are very similar to an existing authorized biological drug (the reference product) and are designed to have no clinically significant variations in terms of safety, effectiveness, and quality from the reference product. Biosimilars have great potential in cancer immunotherapy because they increase treatment accessibility, stimulate competition, lower prices, and provide more sustainable and diverse therapeutic alternatives for cancer patients. For instance, in 2022, according to Amgen Inc., a US-based biopharmaceutical company, the FDA reported 96 proposed biosimilar drugs registered in the FDA's Biosimilar Development Program as of Q2 2022, a nearly 70% increase. Therefore, the increasing emergence of biosimilars is driving the cancer immunotherapy market.
Advanced technologies used in cancer immunotherapy are a key trend gaining popularity in the cancer immunotherapy market. There has been a surge of new technologies and various therapies to help the immune system identify and attack tumors using different therapies and technologies such as immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy. These technologies can make a significant difference in cancer treatment and cure. For instance, in October 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, announced that it had received approval for its Capivasertib in combination with Faslodex. This drug is a cancer immunotherapeutic developed for the treatment of breast cancer and is effective in following recurrence or advancement on or after endocrine therapy in locally progressed or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2).
Major companies operating in the cancer immunotherapy market are focusing on developing innovative products, such as Imjudo in combination with Imfinzi, to better meet the needs of their existing consumers. Imjudo, a combination of Imfinzi (durvalumab) and tremelimumab, is a possible dual immune checkpoint inhibitor in cancer immunotherapy. For instance, in October 2022, AstraZeneca Plc, a UK-based biotechnology and pharmaceutical company, announced the approval of Imjudo and Imfinzi for the treatment of unresectable hepatocellular carcinoma (HCC). The STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) refers to the innovative dose and schedule of the combination, which involves a single dose of the anti-CTLA-4 antibody Imjudo 300mg combined with the anti-PD-L1 antibody Imfinzi 1500mg followed by Imfinzi every four weeks.
In July 2024, Boehringer Ingelheim, a pharmaceutical company based in Germany, acquired Nerio Therapeutics for $1.3 billion. This acquisition will greatly strengthen Boehringer Ingelheim's immuno-oncology portfolio by incorporating Nerio's innovative preclinical program centered on immune checkpoint inhibitors. Nerio Therapeutics, a biotech company located in the US, specializes in drug discovery and development, particularly focusing on phosphatases, which are a challenging but highly promising class of therapeutic protein targets.
Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.
North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the cancer immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The cancer immunotherapy market includes revenues earned by entities by helping the immune system fight cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cancer Immunotherapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cancer immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cancer immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer immunotherapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
- 2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
- 3) By End User: Hospitals, Cancer Research Centers, Clinics
- Subsegments:
- 1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies
- 2) By Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
- 3) By Immunomodulators: Cytokines; Oncolytic Viruses; Toll-Like Receptor (TLR) Agonists
- 4) By Vaccines: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
- 5) By Cell Therapy: CAR T-Cell Therapy; TCR Therapy; Natural Killer (NK) Cell Therapy
- Companies Mentioned: Amgen Inc.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Cancer Immunotherapy Market Characteristics
3. Cancer Immunotherapy Market Trends And Strategies
4. Cancer Immunotherapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Cancer Immunotherapy Growth Analysis And Strategic Analysis Framework
- 5.1. Global Cancer Immunotherapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Cancer Immunotherapy Market Growth Rate Analysis
- 5.4. Global Cancer Immunotherapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Cancer Immunotherapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Cancer Immunotherapy Total Addressable Market (TAM)
6. Cancer Immunotherapy Market Segmentation
- 6.1. Global Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Checkpoint Inhibitors
- Immunomodulators
- Vaccines
- Cell Therapy
- 6.2. Global Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Multiple Myeloma
- 6.3. Global Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Cancer Research Centers
- Clinics
- 6.4. Global Cancer Immunotherapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chimeric Monoclonal Antibodies
- Humanized Monoclonal Antibodies
- Fully Human Monoclonal Antibodies
- 6.5. Global Cancer Immunotherapy Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- PD-1 Inhibitors
- PD-L1 Inhibitors
- CTLA-4 Inhibitors
- 6.6. Global Cancer Immunotherapy Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cytokines
- Oncolytic Viruses
- Toll-Like Receptor (TLR) Agonists
- 6.7. Global Cancer Immunotherapy Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- 6.8. Global Cancer Immunotherapy Market, Sub-Segmentation Of Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- CAR T-Cell Therapy
- TCR Therapy
- Natural Killer (NK) Cell Therapy
7. Cancer Immunotherapy Market Regional And Country Analysis
- 7.1. Global Cancer Immunotherapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Cancer Immunotherapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Cancer Immunotherapy Market
- 8.1. Asia-Pacific Cancer Immunotherapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Cancer Immunotherapy Market
- 9.1. China Cancer Immunotherapy Market Overview
- 9.2. China Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Cancer Immunotherapy Market
- 10.1. India Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Cancer Immunotherapy Market
- 11.1. Japan Cancer Immunotherapy Market Overview
- 11.2. Japan Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Cancer Immunotherapy Market
- 12.1. Australia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Cancer Immunotherapy Market
- 13.1. Indonesia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Cancer Immunotherapy Market
- 14.1. South Korea Cancer Immunotherapy Market Overview
- 14.2. South Korea Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Cancer Immunotherapy Market
- 15.1. Western Europe Cancer Immunotherapy Market Overview
- 15.2. Western Europe Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Cancer Immunotherapy Market
- 16.1. UK Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Cancer Immunotherapy Market
- 17.1. Germany Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Cancer Immunotherapy Market
- 18.1. France Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Cancer Immunotherapy Market
- 19.1. Italy Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Cancer Immunotherapy Market
- 20.1. Spain Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Cancer Immunotherapy Market
- 21.1. Eastern Europe Cancer Immunotherapy Market Overview
- 21.2. Eastern Europe Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Cancer Immunotherapy Market
- 22.1. Russia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Cancer Immunotherapy Market
- 23.1. North America Cancer Immunotherapy Market Overview
- 23.2. North America Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Cancer Immunotherapy Market
- 24.1. USA Cancer Immunotherapy Market Overview
- 24.2. USA Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Cancer Immunotherapy Market
- 25.1. Canada Cancer Immunotherapy Market Overview
- 25.2. Canada Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Cancer Immunotherapy Market
- 26.1. South America Cancer Immunotherapy Market Overview
- 26.2. South America Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Cancer Immunotherapy Market
- 27.1. Brazil Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Cancer Immunotherapy Market
- 28.1. Middle East Cancer Immunotherapy Market Overview
- 28.2. Middle East Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Cancer Immunotherapy Market
- 29.1. Africa Cancer Immunotherapy Market Overview
- 29.2. Africa Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Cancer Immunotherapy Market Competitive Landscape And Company Profiles
- 30.1. Cancer Immunotherapy Market Competitive Landscape
- 30.2. Cancer Immunotherapy Market Company Profiles
- 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
31. Cancer Immunotherapy Market Other Major And Innovative Companies
- 31.1. 3D Signatures Inc.
- 31.2. Adaptive Biotechnologies Corp.
- 31.3. Argos Therapeutics Inc.
- 31.4. Bristol-Myers Squibb Company
- 31.5. Cell Medica Limited
- 31.6. Cellular Biomedicine Group Inc.
- 31.7. Gilead Sciences Inc.
- 31.8. Gradalis Inc.
- 31.9. Immatics Biotechnologies GmbH
- 31.10. Iovance Biotherapeutics Inc.
- 31.11. Juno Therapeutics LLC
- 31.12. Kura Oncology Inc.
- 31.13. MacroGenics Inc.
- 31.14. Merck & Co. Inc.
- 31.15. Neon Therapeutics Inc.
32. Global Cancer Immunotherapy Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Cancer Immunotherapy Market
34. Recent Developments In The Cancer Immunotherapy Market
35. Cancer Immunotherapy Market High Potential Countries, Segments and Strategies
- 35.1 Cancer Immunotherapy Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Cancer Immunotherapy Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Cancer Immunotherapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
